Comparison of in vitro activity of trovafloxacin against Gram-positive and Gram-negative organisms with quinolones and β-lactam antimicrobial agents

Diagnostic Microbiology and Infectious Disease

Volumn 31, Issue 1, 1998, Pages 301-311

  Dembry, Louise M ^a   Roberts, Jenna C ^a   Schock, Kathleen D ^a   Marino, Susan P ^a   Farrel, Patricia A ^a   Andriole, Vincent T ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; BETA LACTAM ANTIBIOTIC; CEFTRIAXONE; CIPROFLOXACIN; IMIPENEM; OFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULTAMICILLIN; TROVAFLOXACIN;

ACCURACY; ALPHA HEMOLYTIC STREPTOCOCCUS; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIUM CULTURE; CITROBACTER; ENTEROBACTER AEROGENES; ENTEROBACTER CLOACAE; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HAEMOPHILUS INFLUENZAE; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; SERRATIA MARCESCENS; STAPHYLOCOCCUS; STENOTROPHOMONAS MALTOPHILIA; STREPTOCOCCUS GROUP G; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES; TECHNIQUE;

4-QUINOLONES; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; BETA-LACTAMS; DRUG EVALUATION, PRECLINICAL; FLUOROQUINOLONES; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; MICROBIAL SENSITIVITY TESTS; NAPHTHYRIDINES;

EID: 0031923220     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0732-8893(98)00004-2     Document Type: Article

References (10)

1. Acar JF, Goldstein FW. Trends in bacterial resistance to fluoroquinolones. Clin Infect Dis. 24:(suppl 1):1997;S67-S73.
2. Brighty KE, Gootz TD. The chemistry and biological profile of trovafloxacin. J Antimicrob Chemother. 39:(suppl B):1997;1-14.
3. Dembry LM, Farrel PA, Orcutt DR, Gerrity LA, Andriole VT. In-vitro activity of trovafloxacin against sensitive and resistant aerobic bacteria using the standard microdilution broth method and Etest. J Antimicrob Chemother. 39:(suppl B):1997;35-42.
4. Eliopoulos GM, Klimm K, Eliopoulos CT, Ferraro MJ, Moellering RC. In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of gram-positive bacteria. Antimicrob Agents Chemother. 37:1993;366-370.
5. Gooding BB, Jones RN. In vitro activity of CP-99,219, a novel azabicyclonaphthyridone. Antimicrob Agents Chemother. 37:1993;349-353.
6. Gootz TD, Brighty KE. Fluoroquinolone antibacterials SAR, mechanism of action, resistance, and clinical aspects . Med Res Rev. 16:1996;433-486.
7. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically, 3rd ed., Approved Standard M7-A3. 1993;NCCLS, Villanova, PA.
8. Neu HC, Chin NX. In vitro activity of the new fluoroquinolone CP-99,219. Antimicrob Agents Chemother. 38:1994;2615-2622.
9. Phillips I, King A, Shannon K. In vitro properties of the quinolones. Andriole VT. The Quinolones. 1988;83-117 Academic Press Inc, San Diego, CA.
10. Thomson KS, Chartrand SA, Sanders CC, Block SL. Trovafloxacin, and new fluoroquinolone with potent activity against Streptococcus pneumoniae. Antimicrob Agents Chemother. 41:1997;478-480.